Filing Analysis
Zura Bio Limited filed an 8-K to furnish a press release via Item 7.01 (Regulation FD Disclosure). The filing does not contain specific financial data or material event details in the body, referring instead to Exhibit 99.1.
📋 Key Facts
- Filing date: December 23, 2024
- The company is an emerging growth company.
- Information provided under Item 7.01 is not considered 'filed' for purposes of Section 18 liability unless specifically stated.
- The filing includes a press release as Exhibit 99.1.
Zura Bio Limited filed an 8-K to furnish a press release via Regulation FD disclosure. The filing does not contain substantive financial data or material changes in this specific document, acting primarily as a vehicle for the attached Exhibit 99.1.
📋 Key Facts
- Filing date: November 25, 2024
- The company is an emerging growth company.
- Information provided under Item 7.01 is not considered 'filed' for purposes of Section 18 liability unless specifically stated.
- Exhibit 99.1 contains the actual press release content.
Zura Bio Limited filed an 8-K to furnish a press release via Item 7.01 (Regulation FD Disclosure). The filing itself contains no substantive financial or corporate changes, acting only as a vehicle for the attached exhibit.
📋 Key Facts
- Filing date: November 14, 2024
- The company is an emerging growth company.
- The report includes Exhibit 99.1 (Press Release) to satisfy Regulation FD requirements.
Zura Bio Limited filed an 8-K to announce its third quarter 2024 financial results. The filing serves as a formal announcement of the earnings release issued on November 7, 2024.
📋 Key Facts
- Reported date: November 7, 2024
- Subject matter: Third Quarter 2024 financial results
- Company status: Emerging growth company
- Exchange: Nasdaq Stock Market (Ticker: ZURA)
Zura Bio Limited filed an 8-K to provide disclosure under Regulation FD, attaching a press release as Exhibit 99.1. The filing does not contain substantive financial data or material event details within the body of the 8-K itself.
📋 Key Facts
- Filed on October 30, 2024
- Company is an emerging growth company
- The filing serves to furnish information via Exhibit 99.1 (Press Release) under Regulation FD
- No specific material event details are provided in the text of this 8-K beyond the reference to the press release.
Zura Bio Limited held its Annual General Meeting of Shareholders on October 23, 2024. The company successfully elected nine directors and re-appointed WithumSmith+Brown, PC as its independent registered public accounting firm.
📋 Key Facts
- Annual Meeting held on October 23, 2024.
- Nine director nominees were elected to the Board of Directors for terms ending at the 2025 annual meeting.
- WithumSmith+Brown, PC was re-appointed as the independent registered public accounting firm for fiscal year 2024.
- Proposal 3 (adjournment of the meeting) was not put to a vote as Proposals 1 and 2 were approved.
Zura Bio Limited announced the separation of its Chief Scientific Officer, Michael Howell, effective October 15, 2024. The company explicitly stated that the departure was not due to disagreements regarding operations or financial practices.
📋 Key Facts
- Michael Howell separated from his role as Chief Scientific Officer on October 15, 2024.
- The separation was not related to the Company's financial or operating results.
- The departure was not due to any disagreements regarding operations, financial, or reporting practices.
Zura Bio Limited provided an updated corporate presentation to facilitate investor meetings and conferences. This filing is a non-binding disclosure under Regulation FD.
📋 Key Facts
- Company released an updated corporate presentation on September 9, 2024.
- The information is filed under Item 7.01 (Regulation FD Disclosure).
- The presentation is intended for use in conferences and investor meetings.
Zura Bio Limited issued a press release via Regulation FD disclosure regarding the issuance of warrants. The filing serves as a formal announcement of information related to Class A Ordinary Shares and Warrants.
📋 Key Facts
- The company is an emerging growth company.
- Warrants (Ticker: ZURAW) are exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share.
- Class A Ordinary Shares trade under the symbol ZURA on the Nasdaq Stock Market.
Zura Bio Limited entered into a share surrender and warrant agreement with entities affiliated with Venrock Healthcare Capital Partners. The transaction involved the cancellation of 4,000,000 Class A ordinary shares in exchange for the issuance of 4,000,000 pre-funded warrants with an exercise price of $0.001 per share.
🚩 Red Flags
- Related-party transaction: The agreement is with entities affiliated with Venrock Healthcare Capital Partners.
- Significant dilution potential: Issuance of 4 million warrants at a nominal exercise price ($0.001) effectively converts existing equity into potentially dilutive instruments, though it maintains the same total economic interest for the holder.
📋 Key Facts
- Date of Agreement: August 15, 2024
- Shareholders (Venrock affiliates) surrendered 4,000,000 Class A ordinary shares for no consideration.
- Company issued 4,000,000 pre-funded warrants to the Shareholders.
- Warrant exercise price: $0.001 per share.
- Warrants have no expiration date and are exercisable immediately.
- Post-transaction totals (as of Aug 21, 2024): 63,207,088 Class A ordinary shares and 23,884,348 pre-funded warrants.
Zura Bio Limited filed an 8-K to provide an updated corporate presentation for use in investor meetings and conferences. The information provided under Item 7.01 is not considered 'filed' for purposes of SEC liability.
📋 Key Facts
- Filed on August 14, 2024.
- Company provided an updated corporate presentation (Exhibit 99.1).
- The filing is under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits).
- Information is intended for use in conferences and investor meetings.
Zura Bio Limited filed an 8-K to announce its second quarter 2024 financial results. The filing serves as a formal announcement of the earnings release dated August 13, 2024.
📋 Key Facts
- Company announced Q2 2024 financial results on August 13, 2024.
- The filing includes an exhibit (99.1) containing the full press release of the results.
- The company is classified as an emerging growth company.
Zura Bio Limited has completed an exchange offer and consent solicitation regarding its IPO warrants. The company is proceeding with a mandatory 'Post-Offer Exchange' to convert remaining untendered IPO warrants into Class A ordinary shares at a reduced ratio.
🚩 Red Flags
- Mandatory conversion of remaining warrants at a diluted/reduced exchange ratio (0.27) for non-participating holders.
- Significant dilution potential as untendered warrants are converted into Class A ordinary shares.
📋 Key Facts
- Completed exchange offer for public warrants (ZURAW) and private placement warrants.
- 97.2% of public warrants (6,703,428 units) were validly tendered in the Exchange Offer.
- 69.0% of private placement warrants (4,080,580 units) were validly tendered.
- The company will execute a 'Post-Offer Exchange' for all remaining untendered IPO warrants on August 27, 2024.
- The exchange ratio for the Post-Offer Exchange is 0.27 Class A ordinary shares per warrant, which is 10% lower than the standard exchange ratio.
Zura Bio Limited announced the successful results of an exchange offer and consent solicitation aimed at eliminating its outstanding IPO warrants. The company successfully tendered approximately 97.2% of public warrants and 69.0% of private placement warrants, allowing for a conversion into Class A ordinary shares.
🚩 Red Flags
- Dilution risk: The Post-Offer Exchange ratio (0.27) is 10% less favorable than the initial exchange offer, which could lead to minor friction with remaining holders, though the high tender rate suggests successful negotiation.
📋 Key Facts
- Exchange Offer Ratio: Holders could receive 0.30 Class A ordinary shares per IPO warrant tendered.
- Post-Offer Exchange Ratio: Remaining untendered warrants will be converted at a lower ratio of 0.27 shares per warrant.
- Public Warrants Tendered: 6,703,428 warrants (approx. 97.2% of outstanding).
- Private Placement Warrants Tendered: 4,080,580 warrants (approx. 69.0% of outstanding).
- The company expects to settle the exchange on or before August 12, 2024.
- The goal is to ensure no IPO warrants remain outstanding following the process.
Zura Bio Limited announced a settlement agreement with former CEO and Founder Someit Sidhu following his departure on April 8, 2024. The agreement outlines specific severance payments and the accelerated vesting of stock options.
🚩 Red Flags
- Significant cash outflow for severance and compensation related to founder departure.
- Large-scale acceleration of equity (1.95M shares) which may lead to future dilution for existing shareholders.
📋 Key Facts
- Settlement Agreement dated July 24, 2024, regarding former CEO Someit Sidhu.
- Company to pay $139,173 in lieu of notice and $139,173 as compensation for termination.
- Severance payment of $278,346 subject to compliance with the Agreement.
- Acceleration of 1,950,000 Class A ordinary shares via stock option grants (1,000,000 fully exercisable; 250,000 vesting over three years).
- 700,000 Option Shares deemed fully exercisable due to participation in a recent capital raise.
Zura Bio Limited has announced an exchange offer and consent solicitation for its outstanding public and private placement warrants. The company is offering to exchange IPO warrants for 0.30 Class A ordinary shares or, via a proposed amendment, 0.27 Class A ordinary shares.
🚩 Red Flags
- Complexity of the dual-track offer (exchange vs. amendment) suggests an attempt to minimize dilution or manage capital structure aggressively.
- The proposed 10% reduction in exchange ratio for non-participating holders (from 0.30 to 0.27) is a coercive tactic often used in warrant recapitalizations.
📋 Key Facts
- Commencement of exchange offer and consent solicitation on July 12, 2024.
- Offer ratio: 0.30 Class A ordinary shares per IPO warrant (public and private placement).
- Proposed amendment ratio: 0.27 Class A ordinary shares for warrants remaining after the offer closes.
- The offer is scheduled to expire at 11:59 p.m. ET on August 8, 2024.
- Requires majority vote of outstanding public and private placement warrants to amend the warrant agreement.
The filing is an amendment to a previous 8-K regarding the CEO transition from Someit Sidhu to Robert Lisicki. It specifically details a retroactive compensation increase for Mr. Lisicki following his promotion.
🚩 Red Flags
- Retroactive compensation adjustment following a leadership transition can sometimes be scrutinized, though common in executive promotions.
📋 Key Facts
- CEO transition from Someit Sidhu to Robert Lisicki was effective April 8, 2024.
- On July 1, 2024, the Board approved an increase in Robert Lisicki's annual base salary from $440,000 to $585,000.
- Target bonus opportunity for the CEO increased from 40% to 50% of annual base salary.
- The compensation changes are retroactive to April 8, 2024.
Zura Bio Limited filed an 8-K to provide a press release via Item 7.01 (Regulation FD Disclosure). The filing itself contains no substantive financial data or material changes, serving primarily as a vehicle for the attached exhibit.
📋 Key Facts
- Filing date: June 14, 2024
- The company is an emerging growth company.
- The report includes a press release as Exhibit 99.1 under Item 7.01.
Zura Bio Limited filed an 8-K to provide a press release under Regulation FD. The filing serves as a vehicle for the company to disclose information to the public via Exhibit 99.1.
📋 Key Facts
- Filing date: June 6, 2024
- The report is filed pursuant to Item 7.01 (Regulation FD Disclosure)
- Information provided under Item 7.01 is intended to be furnished but not 'filed' for purposes of Section 18 liability
- Company is an emerging growth company
Zura Bio Limited filed an 8-K to provide a press release via Item 7.01 (Regulation FD Disclosure). The filing itself contains no substantive financial data or material changes, serving only as a vehicle for the attached exhibit.
📋 Key Facts
- Filing date: June 3, 2024
- The report is filed under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits).
- The filing includes a press release as Exhibit 99.1.
- No specific financial figures or corporate changes are detailed in the text of the 8-K itself.
Zura Bio Limited filed an 8-K to provide a press release under Item 7.01 (Regulation FD Disclosure). The filing itself contains no substantive financial data or material changes, serving primarily as a vehicle for the attached exhibit.
📋 Key Facts
- Filing date: May 29, 2024
- The report is filed pursuant to Item 7.01 (Regulation FD Disclosure)
- Information provided under Item 7.01 is intended to be furnished but not 'filed' for purposes of Section 18 liability
- Includes Exhibit 99.1, a press release dated May 29, 2024
Zura Bio Limited filed an 8-K to announce its first quarter 2024 financial results. The filing serves as a formal announcement of the company's quarterly earnings release.
📋 Key Facts
- Report date: May 9, 2024
- Reporting period: First Quarter 2024
- The company is an emerging growth company.
- Financial results were released via press release (Exhibit 99.1).
Zura Bio Limited completed a private placement of Class A Ordinary Shares and pre-funded warrants, raising approximately $112.5 million in gross proceeds. The offering included participation from both institutional investors and company insiders.
🚩 Red Flags
- Significant dilution potential due to the issuance of over 16 million pre-funded warrants.
- Liquidated damages clause: The company faces a 1.0% penalty on the aggregate subscription amount if registration statements are not filed or made effective within specified deadlines.
📋 Key Facts
- Total gross proceeds: Approximately $112.5 million (before fees/expenses).
- Investor Shares issued: 18,732,301 Class A Ordinary Shares at $3.108 per share.
- Pre-Funded Warrants issued: 16,102,348 warrants to purchase shares at a price of $3.098 ($3.108 - $0.001).
- Insider Shares issued: 1,357,827 Ordinary Shares at $3.13 per share.
- Warrant terms: Exercise price of $0.001; no expiration date unless fully exercised.
- Registration obligation: Company must file registration statements within 35 days of closing and include liquidated damages (1% of interest) for maintenance failures regarding effectiveness.
Zura Bio Limited filed an 8-K to provide a press release under Item 7.01 (Regulation FD Disclosure). The filing serves as a vehicle to disseminate information via Exhibit 99.1.
📋 Key Facts
- Filed on April 8, 2024
- The company is an emerging growth company
- Information provided under Item 7.01 is intended for disclosure purposes and is not considered 'filed' for liability purposes under Section 18 of the Exchange Act.
- Includes a press release as Exhibit 99.1.
Zura Bio Limited announced a leadership transition where founder and CEO Someit Sidhu will step down, to be succeeded by current President and COO Robert Lisicki, effective April 8, 2024. The company also released its full fiscal year 2023 financial results.
🚩 Red Flags
- Sudden leadership transition involving the founder/founding CEO can sometimes signal internal friction, though no specific cause was cited.
- Multiple 8-K items (2.02 and 5.02) in a single filing increase complexity.
📋 Key Facts
- Founder and CEO Someit Sidhu is transitioning out of the CEO role effective April 8, 2024.
- Robert Lisicki (current President and COO) will be promoted to CEO on April 8, 2024.
- Both Dr. Sidhu and Mr. Lisicki will remain as non-independent Directors; Board size increases from nine to ten members.
- The company issued its 2023 full fiscal year financial results via press release on March 28, 2024.
- Dr. Sidhu is credited with leading in-licensing of pipeline molecules (tibulizumab) and completing successful capital raises.
Zura Bio Limited filed an 8-K to disclose the use of an Investor Presentation for communications with banks and analysts. This is a standard regulatory filing used to provide summary information in compliance with Regulation FD.
📋 Key Facts
- The company began making presentations to banks and analysts on March 11, 2024.
- The presentation contains summary information intended for use throughout the fiscal year ending December 31, 2024.
- Information in Exhibit 99.1 is not considered 'filed' under Section 18 of the Exchange Act.
Zura Bio Limited filed an 8-K to provide a press release under Item 7.01 (Regulation FD Disclosure). The filing primarily serves as a vehicle for the company to disseminate information via a press release rather than reporting a specific material corporate event like a merger or bankruptcy.
📋 Key Facts
- Filing date: March 4, 2024
- The report is filed under Item 7.01 (Regulation FD Disclosure).
- Information provided in the attached press release (Exhibit 99.1) is intended to be furnished but not 'filed' for purposes of Section 18 liability.
- Company is an emerging growth company.
Zura Bio Limited has appointed WithumSmith+Brown, PC as its new independent registered public accounting firm, replacing Marcum LLP following a business combination. The change follows the completion of a merger between the Company and Zura.
🚩 Red Flags
- Identification of a material weakness in internal controls regarding the ability to account for complex financial instruments.
- Improper accounting and reporting in historical financial statements concerning certain proceeds from the Company's initial public offering (IPO).
📋 Key Facts
- Effective March 29, 2023, WithumSmith+Brown, PC (Withum) was engaged as the new independent auditor.
- Marcum LLP was terminated as the independent auditor following the business combination on March 20, 2023.
- The previous auditor, Marcum LLP, stated there were no disagreements regarding accounting principles or auditing scope.
- A material weakness in internal controls was identified related to complex financial instruments and improper reporting of IPO proceeds.
Zura Bio Limited filed an 8-K to provide a press release under Regulation FD. The filing does not contain substantive material changes or financial data within the text provided, serving primarily as a vehicle for the attached exhibit.
📋 Key Facts
- Filing date: February 2, 2024
- The company is an emerging growth company.
- Securities registered on Nasdaq include Class A Ordinary Shares (ZURA) and Warrants (ZURAW).
- Warrant exercise price: $11.50 per share.
Zura Bio Limited filed an 8-K to provide notice that it has begun making presentations to banks and analysts using an updated Investor Presentation. This filing is primarily intended to satisfy Regulation FD requirements by making the presentation materials public.
📋 Key Facts
- The company began presenting slides to banks and analysts on January 11, 2024.
- An 'Investor Presentation' dated January 2024 was attached as Exhibit 99.1.
- The presentation contains summary information intended for use in investor/analyst discussions throughout fiscal year 2024.
- The company explicitly states the information is not being 'filed' under Section 18 of the Exchange Act to limit liability.
Zura Bio Limited announced the resignation of its Chief Medical Officer and Executive Vice President, Dr. Chris Cabell, effective January 15, 2024. Simultaneously, the company appointed Robert Lisicki as President and Chief Operating Officer to strengthen its executive leadership.
🚩 Red Flags
- Departure of a key medical officer (CMO) in a biopharmaceutical company can impact clinical development momentum.
- The 'Additional Options' for the new COO are subject to board discretion regarding performance, which is an unusual vesting trigger.
📋 Key Facts
- Dr. Chris Cabell is stepping down as CMO and EVP on January 15, 2024; resignation was not due to any disagreement with management.
- Robert Lisicki appointed as President and COO effective January 8, 2024.
- Lisicki's compensation includes a $440,000 annual base salary and a target discretionary bonus of 40%.
- The company will recommend the granting of 1,000,000 share options to Lisicki as an inducement (600,000 'New Hire Options' and 400,000 'Additional Options').
- Lisicki has a background at Arena Pharmaceuticals (acquired by Pfizer) and Regeneron Pharmaceuticals.
Zura Bio Limited filed an 8-K to provide a press release under Regulation FD. The filing does not contain material financial changes, but serves as a vehicle for public disclosure of company information.
📋 Key Facts
- The filing was submitted on January 3, 2024.
- The report includes an exhibit (99.1) containing a press release dated January 3, 2024.
- The company is an emerging growth company as defined by the SEC.